The purpose of the present study is to assess whether the complement system is activated in the acute phase of ischemic stroke by determining the concentration of complement activation products and the remaining function of the three pathways of…
ID
Source
Brief title
Condition
- Central nervous system vascular disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
see above
Secondary outcome
see above
Background summary
Stroke is the third leading cause of death and the first cause of disability in
developed countries. The need for effective and widely available therapies is
highly evident.
There is growing evidence that inflammation plays an important role in the
pathophysiology of ischemic stroke and may contribute to the secondary damage
following ischemic stroke. Complement activation may be one of the key pathways
in the onset and reinforcement of this inflammation process. Recent animal
studies of focal cerebral ischemia showed that the complement system is
activated and suggested that complement inhibition may improve stroke outcome.
Study objective
The purpose of the present study is to assess whether the complement system is
activated in the acute phase of ischemic stroke by determining the
concentration of complement activation products and the remaining function of
the three pathways of complement activation in peripheral blood of patients
with ischemic stroke.
Study design
Blood samples from 20 patients with ischemic stroke will be collected on
admission and on day 1, 2, 3 and 5 and at 1 month. Plasma will be analyzed for
components of all three pathways of complement activation by an enzyme-linked
immunosorbent assay (ELISA). In addition, plasma will be analyzed for C1q,
CH50, C3a, C5a levels by an ELISA. Stroke severity, neurological improvement or
worsening will be assessed by means of the NIHSS.
Complement levels drawn from ischemic stroke patients will be compared with
complement levels drawn from age and sex matched controls. Regression analysis
will be applied to study the association between complement levels and stroke
severity and complement levels and neurological outcome.
Study burden and risks
Clinical implications Studying the role of the complement system in the acute
phase of ischemic stroke might be very interesting as it may be an important
novel therapeutic target.
postbus 2040
3000 CA Rotterdam
Nederland
postbus 2040
3000 CA Rotterdam
Nederland
Listed location countries
Age
Inclusion criteria
a clinical diagnosis of ischemic stroke, the possibility to confirm the diagnosis with CT or MRI within 24 hours after inclusion in the study and admission within 24 hours of symptom onset.
Exclusion criteria
Patients with symptoms of an infection, malignant or other underlying inflammatory disease and/or currently receiving anti-inflammatory or immunosuppressive medication will be excluded.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL23838.078.08 |